Bridgeway Capital Management, Inc.. recently announced the acquisition of new stake in EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT). The institutional investor has increased its shareholding in the Healthcare company by 40.26% to 0.71 million shares with purchase of 0.2 million shares. This fresh investment now brings its stake to 0.57% valued currently at $0.51 million. In addition, Jane Street Capital LLC raised its holdings by 0.44 million to 0.44 million shares. And Squarepoint OPS LLC has lifted its position by 270.99% or 0.27 million shares – to 0.37 million shares.

With over 1.77 million EyePoint Pharmaceuticals Inc. (EYPT) shares trading Monday and a closing price of $0.54 on the day, the dollar volume was approximately $0.96 million. The shares have shown a negative weekly performance of -12.24% and its price on 08/31/20 lost nearly -4.67%. Currently, there are 124.77M common shares owned by the public and among those 123.92M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for EYPT have a consensus price objective of $2.93. The analysts have set the share’s price value over the next 12 months at a high of $5.00 and a low of $0.80 should the stock experience a downside. Incidentally, analysts’ outlook for the EyePoint Pharmaceuticals Inc. stock is 2.20 for the next 12 months. But an upside of 89.2% will see the stock hit the forecast high price target while mean target price for the stock is $3.00.

Insiders at the company have transacted a total of 20 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 14 of these insider trades were purchases, accounting for 614,891 shares. Insider sales of the common stock occurred on 6 occasions, with total insider shares sold totaling 46,408 shares.

The top 3 mutual fund holders in EyePoint Pharmaceuticals Inc. are FTIF SICAV – Biotechnology Discov, Vanguard Total Stock Market Index, and Franklin Biotechnology Discovery. FTIF SICAV – Biotechnology Discov owns 2.39 million shares of the company’s stock, all valued at over $1.69 million. Franklin Biotechnology Discovery now owns shares totaling to 1.41% of the shares outstanding.

Shares of EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) opened at $0.5308, down -$0.03 from a prior closing price of $0.56. However, the script later closed the day at $0.54, down -4.67%. The company’s stock has a 5-day price change of -12.24% and -36.45% over the past three months. EYPT shares are trading -65.48% year to date (YTD), with the 12-month market performance down to -64.33% lower. It has a 12-month low price of $0.51 and touched a high of $2.69 over the same period. Currently, 1.77 million shares have been traded, compared to an average intraday trading volume of 2.42 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.62%, -23.22%, and -52.07% respectively.

Institutional ownership of EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) shares accounts for 48.80% of the company’s 124.77M shares outstanding. Mutual fund holders own 5.95%, while other institutional holders and individual stakeholders account for 9.32% and 21.60% respectively.

It has a market capitalization of $69.34M and a beta (3y monthly) value of 1.18. The earnings-per-share (ttm) stands at -$0.46. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.87% over the week and 11.36% over the month.

Analysts forecast that EyePoint Pharmaceuticals Inc. (EYPT) will achieve an EPS of -$0.07 for the current quarter, -$0.07 for the next quarter and -$0.22 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.1 while analysts give the company a high EPS estimate of -$0.02. Comparatively, EPS for the current quarter was -$0.15 a year ago. Earnings per share for the fiscal year are expected to decrease by -3.60%, and 38.90% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate EyePoint Pharmaceuticals Inc. (EYPT) as a “Moderate Buy” at a consensus score of 2.20. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 2 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the EYPT, a number of firms have released research notes about the stock. B. Riley FBR stated their Neutral rating for the stock in a research note on April 06, 2020, with the firm’s price target at $4-$1. Laidlaw coverage for the EyePoint Pharmaceuticals Inc. (EYPT) stock in a research note released on November 04, 2019 offered a Buy rating with a price target of $5.